Viz.ai

The collaboration addresses delays in diagnosis and treatment by leveraging AI to help ensure patients with prostate and breast cancer are identified and treated more promptly.  

The AI-powered COPD care coordination tool uses EHR data and natural language processing to identify and manage high-risk patients.

Viz.ai also announced an agreement with Bristol Myers Squibb to identify patients with hypertrophic cardiomyopathy.

Us2.ai announced a similar partnership with Aidoc in October.

The new tool measures the diameter of the ventricles of the heart to provide the ratio of the maximum right ventricle diameter compared with the left ventricle. That can help indicate pulmonary embolism severity.

This new infusion of cash brings the company's total valuation to $1.2 billion. 

The technology will be included in the Viz Intelligent Care Coordination Platform. 

Also, Viz.ai expands AI-powered stroke software to Europe with CE Mark.

Scale Venture Partners and Insight Partners led the financing with participation from Greenoaks, Kleiner Perkins, Threshold Ventures, CRV, Innovation Endeavors and Susa Ventures.   

The Series B round was led by Greenoaks with participation from Threshold Ventures, CRV, GV and Kleiner Perkins.